EXCLUSIVE ONLINE ARTICLES
Research finds patients with chronic HCV infection more likely to develop RA, especially men
Six-week treatment regimen returns same results as 12 weeks in recent study, although researchers...
FEATURED IN THIS ISSUE OF THE RHEUMATOLOGISTJanuary 2015
On Sept. 25, 2013, the Food and Drug Administration (FDA) issued a drug safety communication that described approved modifications to the prescribing information for Rituxan (rituximab) and Arzema (ofatumumab). The changes emphasize the risk of hepatitis B virus (HBV) reactivation with use of these anti-CD20 molecules and provide guidance for screening, monitoring and management of patients to reduce this risk. ...
Everybody is talking about biomarkers! What is a biomarker? According to the NIH Biomarkers Definitions Working Group in 1998, a biomarker is: A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathological processes, or pharmacologic responses to a therapeutic intervention. ...
NEWS FROM THE COLLEGE
The ARHP's Health Professional Online Education Grant is earmarked for nurse practitioners, physician assistants caring for patients with rheumatic diseases.
As state legislatures reconvene, the ACR is identifying states, collaborative partners to help pursue legislation.
A breakdown of the political makeup of Congress as the ACR, RheumPAC gear up to meet, educate newly elected lawmakers.